Join
Live feed
·
INSIDERFilingvia Quantisnow
Oramed Pharmaceuticals Inc. logo

Chief Financial Officer Gabay Avraham sold $330,744 worth of shares (73,360 units at $4.51) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 671,785 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ORMP· Oramed Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORMP (Oramed Pharmaceuticals Inc.) and more on Quantisnow.